The Latest Breaking News from Obesity

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

International Business Times · Nov 1, 2025

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga · Oct 31, 2025

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga · Oct 30, 2025

Viking Therapeutics: High Risk, High Reward Play

Viking Therapeutics stock surges as Phase 3 trials progress for its GLP-1 obesity drug, with analysts seeing major upside potential

MarketBeat · Oct 27, 2025

Gender lens needed to examine weight management

Weight management for women can be impacted by a variety of biological and emotional factors, with experts saying a gender-focused approach is needed.

AAP · Oct 25, 2025

Ventyx Stock Is Rallying Thursday: What's Driving The Surge?

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors.

Benzinga · Oct 23, 2025

Why Ventyx (VTYX) Shares Soared 86.5% After Hours?

Ventyx Biosciences Inc. (NASDAQ:VTYX) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232.

Benzinga · Oct 23, 2025

Anti-obesity drugs have heart health benefits beyond weight loss, study finds

The findings suggest weight loss drugs independently affect heart health risks, researchers said.

Euronews · Oct 23, 2025

Anti-obesity jabs ‘reduce heart attack risk’ regardless of weight lost – study

The benefits extend beyond the loss of weight alone.

The Independent UK · Oct 22, 2025

Trump’s approach to lowering drug costs is raising questions - Roll Call

Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.

Roll Call · Oct 22, 2025